MX2018010272A - Composicion farmaceutica que comprende compuesto heterociclico de seis miembros fusionado con pirrolo. - Google Patents

Composicion farmaceutica que comprende compuesto heterociclico de seis miembros fusionado con pirrolo.

Info

Publication number
MX2018010272A
MX2018010272A MX2018010272A MX2018010272A MX2018010272A MX 2018010272 A MX2018010272 A MX 2018010272A MX 2018010272 A MX2018010272 A MX 2018010272A MX 2018010272 A MX2018010272 A MX 2018010272A MX 2018010272 A MX2018010272 A MX 2018010272A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
pyrrolo
fused
membered heterocyclic
heterocyclic compound
Prior art date
Application number
MX2018010272A
Other languages
English (en)
Inventor
Lu Yun
Zhang Xinhua
Wang Chenyang
Liu Tonghui
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2018010272A publication Critical patent/MX2018010272A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona una composición farmacéutica que comprende un compuesto heterocíclico de seis miembros fusionado con pirrolo o una sal farmacéuticamente aceptable del compuesto. Específicamente, la invención proporciona una composición farmacéutica que comprende 5-(2-dietilamino-etil)-2-(5 -fluoro-2-oxo-1,2-dihidro-indol-3-iliden-metil)-3-5 metil-1,5,6,7-tetrahidro-pirrol o[3,2-c]piridín-4-ona o una sal farmacéuticamente aceptable de lo mismo, y al menos un agente de relleno hidrosoluble. La composición farmacéutica de la invención presenta una rápida disolución y buena estabilidad.
MX2018010272A 2016-03-01 2017-02-28 Composicion farmaceutica que comprende compuesto heterociclico de seis miembros fusionado con pirrolo. MX2018010272A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610116472 2016-03-01
PCT/CN2017/075111 WO2017148359A1 (zh) 2016-03-01 2017-02-28 一种含有吡咯并六元杂环化合物或其可药用盐的药物组合物

Publications (1)

Publication Number Publication Date
MX2018010272A true MX2018010272A (es) 2018-12-19

Family

ID=59743470

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010272A MX2018010272A (es) 2016-03-01 2017-02-28 Composicion farmaceutica que comprende compuesto heterociclico de seis miembros fusionado con pirrolo.

Country Status (17)

Country Link
US (1) US10973807B2 (es)
EP (1) EP3424500B1 (es)
JP (1) JP6948760B2 (es)
KR (1) KR20180112066A (es)
CN (1) CN107530331B (es)
AU (1) AU2017226420B2 (es)
BR (1) BR112018017155A2 (es)
CA (1) CA3015249A1 (es)
DK (1) DK3424500T3 (es)
ES (1) ES2907376T3 (es)
HU (1) HUE057830T2 (es)
MX (1) MX2018010272A (es)
PL (1) PL3424500T3 (es)
PT (1) PT3424500T (es)
RU (1) RU2737734C2 (es)
TW (1) TWI750152B (es)
WO (1) WO2017148359A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111184693B (zh) * 2019-05-29 2023-07-21 百济神州(苏州)生物科技有限公司 一种raf激酶抑制剂制剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008009557A (es) 2006-01-27 2009-01-07 Shanghai Hengrui Pharm Co Ltd Inhibidores de la cinasa de proteina de la pirrolo [3,2-c] piridin-4-ona-2-indolinona.
CN101007815B (zh) * 2006-01-27 2010-06-23 江苏恒瑞医药股份有限公司 吡咯并六元杂环化合物及其在医药上的用途
CN101007814A (zh) * 2006-01-27 2007-08-01 上海恒瑞医药有限公司 吡咯并六元杂环化合物及其在医药上的用途
EP2113248A1 (en) * 2008-04-29 2009-11-04 Ratiopharm GmbH Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
EP2468258A1 (en) * 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
CN102266300B (zh) * 2011-07-14 2013-01-02 广东药学院 一种吉非替尼分散片及其制备方法和应用

Also Published As

Publication number Publication date
AU2017226420A1 (en) 2018-08-30
BR112018017155A2 (pt) 2018-12-26
WO2017148359A1 (zh) 2017-09-08
JP2019507151A (ja) 2019-03-14
EP3424500A1 (en) 2019-01-09
CN107530331A (zh) 2018-01-02
DK3424500T3 (da) 2022-02-21
CN107530331B (zh) 2018-12-04
RU2018132929A3 (es) 2020-05-13
RU2737734C2 (ru) 2020-12-02
CA3015249A1 (en) 2017-09-08
EP3424500A4 (en) 2019-10-02
PL3424500T3 (pl) 2022-04-04
JP6948760B2 (ja) 2021-10-13
US10973807B2 (en) 2021-04-13
RU2018132929A (ru) 2020-04-01
HUE057830T2 (hu) 2022-06-28
AU2017226420B2 (en) 2022-07-07
TWI750152B (zh) 2021-12-21
TW201731508A (zh) 2017-09-16
US20190054073A1 (en) 2019-02-21
KR20180112066A (ko) 2018-10-11
ES2907376T3 (es) 2022-04-25
EP3424500B1 (en) 2022-01-26
PT3424500T (pt) 2022-02-07

Similar Documents

Publication Publication Date Title
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
GEP20217285B (en) BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS
EP3539963A4 (en) NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE
PH12016502539A1 (en) Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
WO2013163244A8 (en) Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
AU2015336400A8 (en) Novel Aminoalkyl benzothiazepine Derivatives And Uses Thereof
WO2016011390A8 (en) Irak4 inhibiting agents
MX2020011652A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
NZ715745A (en) Formulation of syk inhibitors
WO2015171526A3 (en) Tricyclic pyrazolopyridine compounds
HUE056922T2 (hu) 2-szubsztituált amino-naft[1,2-D]imidazol-5-on vegyületek vagy azok gyógyszerészetileg elfogadható sói
MY186598A (en) Carboxamide derivatives
EA201692298A1 (ru) Производные карбоксамидов
PH12016502405A1 (en) 2-acylaminothiazole derivative or salt thereof
CA3042181C (en) Pharmaceutical composition for preventing and treating nonalcoholic steatohepatitis, hepatic fibrosis, and liver cirrhosis, comprising adenosine derivatives
ZA201804663B (en) C-glycoside derivatives having fused phenyl ring or pharmaceutically acceptable salts thereof, method for preparing the same and pharmaceutical composition comprising the same
GB2590189B (en) Lycorine derivative, and pharmaceutical composition and use thereof
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
MX2018010272A (es) Composicion farmaceutica que comprende compuesto heterociclico de seis miembros fusionado con pirrolo.
EP3569242A4 (en) PHARMACEUTICAL COMPOSITION WITH SULGLYCOTIDE OR PHARMACEUTICALLY SAFE SALT THEREOF FOR THE PREVENTION OR TREATMENT OF DRY EYES
EP3483149A4 (en) BENZO [D] THIAZOLE DERIVATIVE OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
EP3530654A4 (en) CARBOXYLIC ACID COMPOUND WITH QUINOLINYL SUBSTITUTE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF
PH12020550763A1 (en) Pyridinone derivatives and their use as selective alk-2 inhibitors
MX2018004505A (es) Suspensiones orales fisica y quimicamente estables de givinostat.
SI3778609T1 (sl) Derivati penama ali njenih soli, farmacevtski sestavki in njihova uporaba